Paulina Czajka-Francuz1, Tomasz Francuz2, Sylwia Cisoń-Jurek1, Aleksander Czajka3, Marcin Fajkis1, Bożena Szymczak1, Maciej Kozaczka4, Krzysztof Piotr Malinowski5, Wojciech Zasada6, Jerzy Wojnar1, Jerzy Chudek1. 1. Department of Internal Medicine and Oncology, Silesian Medical University, ul. Reymonta 8, 40-027 Katowice, Poland. 2. Department of Biochemistry, Silesian Medical University, ul. Medyków 18, 40-752 Katowice, Poland. 3. Department of General and Vascular Surgery, Silesian Medical University, Ziołowa 45/47, 40-635 Katowice, Poland. 4. National Institute of Oncology, Public Research Institute in Gliwice, Department of Radiotherapy and Chemotherapy, 44-101 Gliwice, Wybrzeże Armii Krajowej 15, Poland. 5. Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland. 6. 2nd Department of Cardiology, University Hospital in Krakow, Poland.
Abstract
AIM: Comparison of 14 cytokines levels between a control group and prospectively enrolled CRC patients to confirm their significance in CRC development. We tested if a model based on 14 cytokines levels could predict prognosis in Caucasian CRC patients treated with 5-FU based chemotherapy. BACKGROUND: Novel prognostic tools in colorectal cancer (CRC) are necessary to optimize treatment, reduce toxicity and chemotherapy (CHT) costs. MATERIALS AND METHODS: We assessed prognostic significance of 14 cytokines: IL-1 beta, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL-17A in 75 prospectively enrolled CRC patients before initiation of palliative or adjuvant CHT and in 22 control subjects. Readings were taken using the Bio-Plex 200 System. Response to treatment was assessed after 6 months from initiation of CHT. The treated group was divided depending on the response into a progressors (death, progression of disease) and non-progressors group (stable disease, partial response, complete response). RESULTS: We found that increased concentration of IL-8 was a negative prognostic factor in the whole group and palliative subgroup, whereas increased level of IL-10, IL-7, and IL-12p70 was a negative predictor in the adjuvant group CHT. CONCLUSIONS: We proposed a statistical model based on circulating cytokine levels, showing a good prognostic value in prediction of the response to CHT (AUC = 0.956). The model, including combined IL-2, IL-8, IL-10 and IL-13 levels, established in the whole treated group, should be validated in larger trials.
AIM: Comparison of 14 cytokines levels between a control group and prospectively enrolled CRC patients to confirm their significance in CRC development. We tested if a model based on 14 cytokines levels could predict prognosis in Caucasian CRC patients treated with 5-FU based chemotherapy. BACKGROUND: Novel prognostic tools in colorectal cancer (CRC) are necessary to optimize treatment, reduce toxicity and chemotherapy (CHT) costs. MATERIALS AND METHODS: We assessed prognostic significance of 14 cytokines: IL-1 beta, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL12p70, IL-13, IL-17A in 75 prospectively enrolled CRC patients before initiation of palliative or adjuvant CHT and in 22 control subjects. Readings were taken using the Bio-Plex 200 System. Response to treatment was assessed after 6 months from initiation of CHT. The treated group was divided depending on the response into a progressors (death, progression of disease) and non-progressors group (stable disease, partial response, complete response). RESULTS: We found that increased concentration of IL-8 was a negative prognostic factor in the whole group and palliative subgroup, whereas increased level of IL-10, IL-7, and IL-12p70 was a negative predictor in the adjuvant group CHT. CONCLUSIONS: We proposed a statistical model based on circulating cytokine levels, showing a good prognostic value in prediction of the response to CHT (AUC = 0.956). The model, including combined IL-2, IL-8, IL-10 and IL-13 levels, established in the whole treated group, should be validated in larger trials.
Authors: Peter K Baier; Guido Wolff-Vorbeck; Stephan Eggstein; Ulrich Baumgartner; Ulrich T Hopt Journal: Anticancer Res Date: 2005 May-Jun Impact factor: 2.480
Authors: Steven A Rosenberg; Claude Sportès; Mojgan Ahmadzadeh; Terry J Fry; Lien T Ngo; Susan L Schwarz; Maryalice Stetler-Stevenson; Kathleen E Morton; Sharon A Mavroukakis; Michel Morre; Renaud Buffet; Crystal L Mackall; Ronald E Gress Journal: J Immunother Date: 2006 May-Jun Impact factor: 4.456
Authors: Paulina Czajka-Francuz; Sylwia Cisoń-Jurek; Aleksander Czajka; Maciej Kozaczka; Jerzy Wojnar; Jerzy Chudek; Tomasz Francuz Journal: Int J Mol Sci Date: 2021-12-23 Impact factor: 5.923